HC Wainwright Issues Negative Outlook for ETON Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Eton Pharmaceuticals in a research note issued on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their previous estimate of $0.05. HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share.

ETON has been the topic of several other research reports. Craig Hallum lifted their target price on Eton Pharmaceuticals from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. B. Riley started coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 target price on the stock.

Eton Pharmaceuticals Trading Up 2.6 %

Shares of ETON opened at $16.67 on Friday. The business’s 50 day moving average is $12.84 and its 200 day moving average is $8.25. The company has a market capitalization of $434.27 million, a PE ratio of -75.77 and a beta of 1.38. Eton Pharmaceuticals has a 12-month low of $3.03 and a 12-month high of $17.00.

Institutional Trading of Eton Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ETON. Point72 Asia Singapore Pte. Ltd. bought a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $54,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals in the 3rd quarter worth approximately $90,000. Renaissance Technologies LLC boosted its holdings in shares of Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after purchasing an additional 41,469 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $362,000. Finally, Baader Bank Aktiengesellschaft purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $373,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.